Александр Михайлович Шевченко

Александр Михайлович Шевченко

Auto-generated profile, based on publicly available information

Александр Михайлович Шевченко

Pyatigorsk Medical and Pharmaceutical Institute

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2020 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
VKVictoria Kishchenko
Victoria Kishchenko
VVVladislav Vernikovsky
Vladislav Vernikovsky
IPIgor Privalov
Igor Privalov
ASAleksander Shevchenko
Aleksander Shevchenko
Since the moment of their appearance in the second half of the 20th century, application forms have attracted the attention of the specialists involved in the skin application of pharmacologically active agents. Herewith, both localized exposure to the external integuments and the possibility of achieving a systemic effect, are of interest. The range of products used in modern films, is also wide – from pharmaceutical substances to biologically active components of cosmetics.The aimof the present work is to study the current state of research in the field of the creation and improvement of medicinal and cosmeceutical films.Materials and methods.The study was conducted on the base of patent information (fips.ru, findpatent.ru) and information and search databases - the State register of medicines (grls.rosminzdrav.ru) and the data from the Federal accreditation service (www.fsa.gov.ru), as well as scientific libraries (Google Scholar, eLIBRARY, PubMed) and reference literature.Results.Native and foreign medicinal films have longer than a 50-year history of their existence in the pharmaceutical market. Modern scientists’ interest in this application form, does not fade away due to a great number of its positive characteristics. In addition to pharmaceutical applications, films are widely used in cosmetics in the form of masks applied to the skin. Biologically active substances are widely used in cosmetics which, in recent years, has led to the emergence of a group of cosmeceutical products that combine medical and cosmetic films. The article also discusses film manufacturing technology, active substances, as well as polymers used for medicinal and cosmetic films presented in the Russian market.Conclusion.The analysis of the literature data makes it possible to conclude that the development of films is promising in both medicine and cosmeceuticals.

29 May 2021 in Drug development & registration
Verified
Journal Article
Open access
PDF file
ADA. M. Domanina
A. M. Domanina
MCM. V. Chernikov
M. V. Chernikov
IRIrina P. Remezova
Irina P. Remezova
ESE. F. Stepanova
E. F. Stepanova
ASA. M. Shevchenko
A. M. Shevchenko
AMA. V. Morozov
A. V. Morozov
Introduction. Currently, for the treatment of gastric ulcer, drugs with a combined effect are used. To eliminate possible side effects of the drugs used, the search for new molecules to create more effective and safe histamine H2 receptors continues. As a possible solution to these problems, we investigated the substance dinitrate of 2-phenyl-9-diethylaminoethylimidazo[1,2-α]benzimidazole (DFDB).Aim. The aim of this study was to obtain 2-phenyl-9-diethylaminoethylimidazo[1,2-α]benzimidazole dinitrate tablets and develop methods for quality control.Materials and methods. The object of study was tablets based on the substance DF DB. The physicochemical and technological properties of the tablet dosage form were studied. Pharmaco-technological and physico-chemical indicators were determined according to the methods of the State Pharmacopoeia of the XIV edition. Identification and quantitative determination of DFDB in tablets was performed by HPLC.Results and discussion. Based on the physico-chemical properties and determination of the main technological indicators of DFDB, an optimal tableting technology has been developed. The optimal composition of tablets has been developed. Identification of tablets is proposed to be carried out using HPLC in comparison with the standard sample of DFDB. Related impurities, according to the data obtained, do not exceed 0.1 %. We found that the tablets do not have an antimicrobial effect. The analyzed tablets correspond to category 3A. The content of DFDB should be from 95 to 105 % of the declared amount in one tablet. During the analysis, we conducted biopharmaceutical and technological studies of the finished dosage form during storage under the conditions of long-term stability testing in polymer cans with screw-on lids. It is shown that the selected composition of excipients and the production technology ensure the stability of the finished dosage form for two years of storage under the observed conditions. To select the tableting technology, the main technological properties of the DFDB substance are analyzed. The choice of excipients and the composition of the film coating was carried out.Conclusion. The technology is developed and standardization of tablets based on the substance DFDB is proposed.

1 May 2025 in Regulatory Research and Medicine Evaluation
Verified
Journal Article
Open access
PDF file
VKV. V. Kosenko
V. V. Kosenko
ABA. V. Bolotova
A. V. Bolotova
AGA. S. Gavrilov
A. S. Gavrilov
NBN. D. Bunyatyan
N. D. Bunyatyan
VEVladimir Evteev
Vladimir Evteev
APA. B. Prokofiev
A. B. Prokofiev
INRODUCTION. The traditional technology of layering components onto sugar gra­nules to produce medicinal products in the form of dragees has a number of disadvantages, including labour intensity, as well as the exposure of intermediates to liquids and high temperatures at certain production stages, which reduces the stability and effectiveness of the resulting medicinal products.AIM. This study aimed to develop an alternative technology for producing coated spherical tablet cores, with a multivitamin product as a case study.MATERIALS AND METHODS. The active ingredients used were retinol acetate, ascorbic acid, thiamine hydrochloride, and riboflavin. The excipients used included fillers (glucose, sorbitol, isomalt, and microcrystalline cellulose), glidants (talc and magnesium stearate), coating components (hydroxypropyl methylcellulose and titanium dioxide), etc. Tablet masses were produced by mixing accurately weighed amounts of active substances and excipients in a mixer for powdered materials. Individual tablet cores and tablets were weighed using a Shimadzu UW220H labo­ratory balance. They were tested for resistance to crushing using an Erweka TBH 125 tablet hardness tester. The content of water-soluble vitamins was determined by high-performance liquid chromatography (HPLC) in accordance with analytical procedures developed for Revit dragees by Uralbiofarm JSC. The labour intensity of multivitamin manufacturing technologies was estimated as the time required to produce a package of 100 dragees (by production process stage), and their efficiency was evaluated based on the process yield.RESULTS. As an alternative to the traditional technology for producing dragees, the authors developed a new direct compression and coating technology involving the use of 7.0 mm concave punches with a 4 mm curvature radius to obtain spherical tablet cores for coating. Pilot-scale industrial tests confirmed smooth equipment operation and compliance of tablet cores/finished medicinal products with the applicable regulatory requirements. This study demonstrated the possibility of producing spherical tablet cores with a mass of 0.27±0.01 g, friability of 0.6±0.1%, disintegration time of 4.3±1.2 min, and resistance to crushing of 48.2±7.4 N. Subsequent coating of tablet cores resulted in finished medicinal products indistinguishable in appearance from traditional dragees. The yield of finished medicinal products was 87.14% for sugar-coated tablet cores and 91.07% for suspension-coated tablet cores. The study showed the traditional technology for producing dragees to be 1.8 times more labour intensive than direct compression and coating of tablet cores. Compared with vitamins formulated as traditional dragees, sugar-coated and suspension-coated tablet cores exhibited superior stability over 12 months.CONCLUSIONS. The direct compression technology proposed for producing spherical tablet cores for subsequent coating instead of the traditional dragee technology will increase production efficiency, improve the stability of active components during storage, and reduce the duration and labour intensity of the production process. The proposed technology can be recommended to dragee manufacturers for implementation in industrial production.

23 December 2019 in Химико-фармацевтический журнал
Verified
Journal Article
Closed access
PDF file
АЛАнна Владимировна Ланцова
Анна Владимировна Ланцова
ЮОЮрий Витальевич Олефир
Юрий Витальевич Олефир
НБНаталья Дмитриевна Бунятян
Наталья Дмитриевна Бунятян
ЕСЕкатерина Викторовна Санарова
Екатерина Викторовна Санарова
ОООльга Львовна Орлова
Ольга Львовна Орлова
АПАлексей Борисович Прокофьев
Алексей Борисович Прокофьев
Валидирована методика количественного определения вспомогательных компонентов (сахарозы, фосфатидилхолина и холестерина), входящих в состав липосомальной лекарственной формы фотосенсибилизатора из группы фталоцианинов — липофталоцина — методом ТСХ с хроматоденситометрией. Коэффициент стандартного остаточного отклонения при установлении линейности составил для сахарозы 3,48, фосфатидилхолина — 1,69, холестерина — 1,36. Коэффициент вариации при определении сходимости и промежуточной прецизионности составил меньше 5 %. Надежность метода установлена в широком диапазоне различных условий пригодности системы.

10 May 2020 in "Medical & Pharmaceutical Journal "Pulse"
Verified
Journal Article
Closed access
ASA.M. Shevchenko
A.M. Shevchenko
VBV.V. Baranova
V.V. Baranova
NKN.N. Krylov
N.N. Krylov

25 November 2025 in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
Verified
Journal Article
Closed access
ASA. B. Sannikov
A. B. Sannikov
ESE. V. Shaydakov
E. V. Shaydakov
ESE. A. Shcheglov
E. A. Shcheglov
ASA. M. Shevchenko
A. M. Shevchenko
AMA. Zh. Meltsova
A. Zh. Meltsova
IKI. A. Klubkova
I. A. Klubkova
Introduction . The use of various venotonic drugs is an integral part of the comprehensive treatment of patients with chronic venous diseases (CVD). Aim . To evaluate the clinical efficacy of a new domestic biologically active supplement (BAS) consisting of the flavonoid hesperidin methyl chalcone (HMC), troxerutin (HER) and ascorbic acid (VitC) in the complex treatment of patients with CVD of clinical classes C1–C3 (according to CEAP). Materials and methods . The open, comparative multicenter, prospective study included 281 patients with CVD (varicose veins) of clinical classes C1–C3 (according to CEAR). The first (studied) group of patients included 158 people who received Russian biologically active supplement (HMC + HER + VitC) for two months. The second (control) group consisted of 123 patients who did not receive biologically active supplement. In order to study the effectiveness of BAS sequentially during three patient visits, a statistical analysis of changes in quality of life according to the CIVIQ-2 questionnaire, pain intensity using a visual analog scale (VAS) and the dynamics of changes in malleolar volume (MV) on the target limb under study was performed. Results . The results of the conducted studies have shown that the inclusion of a new Russian biologically active supplement (HMC + HER +VitC) in the complex treatment of patients with CVD significantly reduces symptoms and improves the quality of life of patients. The maximum effectiveness of Russian biologically active supplement (HMC + HER + VitC) is manifested after 2 months of use in standard dosages without any side effects. The main advantage of the new biologically active supplement is its complete solubility in water and, as a result, higher bioavailability. Conclusions . The results of the conducted studies have shown that the inclusion of a new Russian biologically active supplement supplement (HMC + HER + VitC) in the complex treatment of patients with CVD significantly reduces symptoms and improves the quality oflife of patients.